Company intelligence / Profile preview
BrightGene Bio-Medical Technology
Suzhou, Jiangsu, Chinabright-gene.com ↗
- Ownership
- Public · 688166
- Development stage
- Commercial
01
Overview
BGC-0228, a long-acting peptide-drug conjugate targeting CD44 antigen, is in Phase 1 for various solid tumors. The company develops multiple innovative and generic drug programs spanning oncology, diabetes, infectious diseases, and immunology. Some specialty generics are commercial.
- Therapeutic areas
- EndocrinologyOphthalmologyInfectious DiseasesGastroenterologyCardiovascularOncology
- Modalities
- Small moleculePeptidesAntibody-drug conjugateSynthetic peptidePeptide-drug conjugateBiologic
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on BrightGene Bio-Medical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BrightGene Bio-Medical Technology.